Switch theme
Sign up to access all valuation multiples
Liaoning Chengda Biotechnology Co Ltd is engaged in the research and development, production and sales of human vaccines.
2002
n/a
LTM Revenue $241M
LTM EBITDA $74.2M
$765M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Liaoning Chengda Biotech has a last 12-month revenue (LTM) of $241M and a last 12-month EBITDA of $74.2M.
In the most recent fiscal year, Liaoning Chengda Biotech achieved revenue of $233M and an EBITDA of $80.1M.
Liaoning Chengda Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Liaoning Chengda Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $241M | XXX | $233M | XXX | XXX | XXX |
| Gross Profit | $199M | XXX | $193M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | $74.2M | XXX | $80.1M | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 34% | XXX | XXX | XXX |
| EBIT | $60.3M | XXX | $63.0M | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $50.9M | XXX | $47.6M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Liaoning Chengda Biotech's stock price is CNY 26 (or $4).
Liaoning Chengda Biotech has current market cap of CNY 10.9B (or $1.5B), and EV of CNY 5.5B (or $765M).
See Liaoning Chengda Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $765M | $1.5B | XXX | XXX | XXX | XXX | $0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Liaoning Chengda Biotech has market cap of $1.5B and EV of $765M.
Liaoning Chengda Biotech's trades at 3.3x EV/Revenue multiple, and 9.6x EV/EBITDA.
Equity research analysts estimate Liaoning Chengda Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Liaoning Chengda Biotech has a P/E ratio of 29.7x.
See valuation multiples for Liaoning Chengda Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $765M | XXX | $765M | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 10.3x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 12.7x | XXX | 12.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 29.7x | XXX | 31.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 39.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLiaoning Chengda Biotech's last 12 month revenue growth is 10%
Liaoning Chengda Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Liaoning Chengda Biotech's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Liaoning Chengda Biotech's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Liaoning Chengda Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | -11% | XXX | XXX | XXX |
| Rule of 40 | 50% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Liaoning Chengda Biotech acquired XXX companies to date.
Last acquisition by Liaoning Chengda Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Liaoning Chengda Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Liaoning Chengda Biotech founded? | Liaoning Chengda Biotech was founded in 2002. |
| Where is Liaoning Chengda Biotech headquartered? | Liaoning Chengda Biotech is headquartered in China. |
| Is Liaoning Chengda Biotech publicy listed? | Yes, Liaoning Chengda Biotech is a public company listed on SHG. |
| What is the stock symbol of Liaoning Chengda Biotech? | Liaoning Chengda Biotech trades under 688739 ticker. |
| When did Liaoning Chengda Biotech go public? | Liaoning Chengda Biotech went public in 2021. |
| Who are competitors of Liaoning Chengda Biotech? | Similar companies to Liaoning Chengda Biotech include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Liaoning Chengda Biotech? | Liaoning Chengda Biotech's current market cap is $1.5B |
| What is the current revenue of Liaoning Chengda Biotech? | Liaoning Chengda Biotech's last 12 months revenue is $241M. |
| What is the current revenue growth of Liaoning Chengda Biotech? | Liaoning Chengda Biotech revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Liaoning Chengda Biotech? | Current revenue multiple of Liaoning Chengda Biotech is 3.2x. |
| Is Liaoning Chengda Biotech profitable? | Yes, Liaoning Chengda Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Liaoning Chengda Biotech? | Liaoning Chengda Biotech's last 12 months EBITDA is $74.2M. |
| What is Liaoning Chengda Biotech's EBITDA margin? | Liaoning Chengda Biotech's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Liaoning Chengda Biotech? | Current EBITDA multiple of Liaoning Chengda Biotech is 10.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
